Advanced　renal　cell　carcinoma　and　triple　negative　breast　cancer　(TNBC)　are　malignancies　without　effective　therapeutics　currently.　Ursolic　acid　(UA)　has　been　previously　reported　to　have　anti-cancer　effects　in　multiple　solid　tumors.　In　order　to　develop　more　potent　anti-cancer　reagents,　FZU-03,010　based　on　the　chemical　structure　of　UA　were　synthesized.　The　results　demonstrated　that,　compared　with　UA,　FZU-03,010　could　suppress　renal　cancer　cell　786-0　and　TNBC　cell　HCC1806　cell　viability　more　potently.　Furthermore,　FZU-03,010　could　induce　G1　cell　cycle　arrest　and　cell　apoptosis　more　efficiently　than　UA.　FZU-03,010　could　also　inhibit　signal　transducer　and　activator　of　transcription　3　activation,　induce　the　expression　of　cell　cycle-dependent　kinase　inhibitors　(p21　and　p27)　and　promote　cell　apoptosis.　In　conclusion,　our　results　suggest　that　the　UA　derivative　FZU-03,010　is　more　potent　in　inhibiting　cancer　cell　survival,　and　FZU-03,010　has　the　potential　to　be　developed　as　a　therapeutic　for　renal　cell　cancers　and　TNBCs.